[How should severe and chronic atopic dermatitis in children be managed?]

Area of Science:

• Pediatric Dermatology
• Immunodermatology

Background:

• Severe atopic dermatitis in children is uncommon but poses significant challenges.
• Failure to respond to conventional therapies (corticosteroids, topical immunosuppressors) necessitates evaluation for appropriate advanced treatment.
• Accurate diagnosis and assessment of treatment resistance are crucial before initiating specialized interventions.

Purpose of the Study:

• To review current evidence and expert opinion on managing severe, refractory childhood atopic dermatitis.
• To discuss the role and safety of established and emerging exceptional treatments in pediatric patients.
• To highlight the need for further research and personalized treatment strategies.

Main Methods:

• Review of existing literature on immunosuppressive therapies, phototherapy, and other treatments for severe atopic dermatitis in children.
• Discussion of clinical experience and expert consensus regarding the use of cyclosporine and other agents.
• Identification of knowledge gaps and areas requiring further investigation.

Main Results:

• Cyclosporine is a frequently used, albeit unapproved, immunosuppressant for severe pediatric atopic dermatitis, requiring careful monitoring for nephrotoxicity.
• Limited data exists for other immunosuppressants (azathioprine, mycophenolate mofetil, interferon gamma) in this population, necessitating large-scale comparative studies.
• Phototherapy may be considered, but its application in children needs further definition and long-term monitoring.
• Antileukotrienes have not shown sufficient efficacy for severe cases.

Conclusions:

• Management of severe pediatric atopic dermatitis involves careful patient assessment and consideration of off-label treatments like cyclosporine under strict supervision.
• Further research, including large cohort studies and in vitro predictive tests, is essential to optimize the use of exceptional therapies and develop new targeted treatments.
• A comprehensive approach emphasizing patient education, monitoring, and physician availability is paramount.